title: Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
abstract: We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy. The safety and efficacy of TAF in patients with TDF-associated renal tubulopathy and multiple drug resistant HIV has not yet been described. TAF may represent a useful option to maximally suppress HIV in patients with these complications.
authors.affiliation: Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Mikula
authors.affiliation: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Maura M
authors.initials: MM
authors.lastname: Manion
authors.affiliation: HIV Drug Resistance Program, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Frank
authors.initials: F
authors.lastname: Maldarelli
authors.affiliation: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Lucila M
authors.initials: LM
authors.lastname: Suarez
authors.affiliation: Clinical Center, NIH, Bethesda, MD, USA.
authors.forename: Jaha F
authors.initials: JF
authors.lastname: Norman-Wheeler
authors.affiliation: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Alex G
authors.initials: AG
authors.lastname: Ober
authors.affiliation: Applied and Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
authors.forename: Robin L
authors.initials: RL
authors.lastname: Dewar
authors.affiliation: National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Kopp
authors.affiliation: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: H Clifford
authors.initials: HC
authors.lastname: Lane
authors.affiliation: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Alice K
authors.initials: AK
authors.lastname: Pau
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000503:physiopathology; D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000409:Alanine; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy; D000068698:Tenofovir / Q000009:adverse effects* / Q000031:analogs & derivatives
chemical_list: D019380:Anti-HIV Agents; D000068698:Tenofovir; C442442:tenofovir alafenamide; D000225:Adenine; D000409:Alanine